[1]耿　芳　马雷雷　李　静　姜　晨.中西医药治疗肾性贫血的研究进展[J].大众科技,2021,23(11):103-108.
　Research Progress of Chinese and Western Medicine in the Treatment of Renal Anemia[J].Popular Science & Technology,2021,23(11):103-108.
点击复制

中西医药治疗肾性贫血的研究进展()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
23
期数:
2021年11
页码:
103-108
栏目:
医药与卫生
出版日期:
2021-11-20

文章信息/Info

Title:
Research Progress of Chinese and Western Medicine in the Treatment of Renal Anemia
作者:
耿　芳1　马雷雷3　李　静2　姜　晨3　
（1.河北省沧州中西医结合医院，河北 沧州 061000；2.天津中医药大学，天津 301617； 3.天津中医药大学第一附属医院，天津 300381）
关键词:
肾性贫血; 中西医; 经方; 研究进展
Keywords:
renal anemia traditional Chinese and eestern medicine prescription research progress
文献标志码:
A
摘要:
肾性贫血是慢性肾脏病（chronic renal failure，CKD）3-5期常见的并发症之一，且肾性贫血是影响住院率和死亡率的重要危险因素，且进一步加重我国CKD患者的经济负担，文章从肾性贫血的西医机制、中医病机、中医治疗、西医治疗现状等方面汇总近年来相关文献记录，总结肾性贫血的中西医在治疗肾性贫血方面具有独特的优势，为中西医结合治疗肾性贫血提供理论依据。
Abstract:
Renal anemia is one of the common complications of chronic kidney disease (CKD) stage 3-5, and renal anemia is an important risk factor affecting hospitalization rate and mortality, and further aggravates the economic burden of CKD patients in China. This paper summarizes the relevant literature records in recent years from the aspects of western medicine mechanism, pathogenesis, treatment and current situation of western medicine of renal anemia, to summarize the unique advantages of traditional Chinese and western medicine in the treatment of renal anemia, so as to provide a theoretical basis for the treatment of renal anemia with integrated traditional Chinese and western medicine.

参考文献/References:

[1]　Li Y, Shi H, Wang W, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease[J]. Medicine, 2016, 95(24):e3872. [2]　林攀，丁小强，袁敏，等. 慢性肾脏病患者贫血患病现况调查[J]. 复旦大学学报(医学版)，2009，36(5): 562-565. [3]　左力，刘雪丽，韩晟. 肾性贫血加重中国慢性肾脏病患者经济负担的研究[J]. 中国药物经济学，2018(9): 11-16. [4]　Li Y, Shi H, Wang W M, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study[J]. Medicine(Baltimore), 2017, 95(24): e3872. [5]　中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识[J]. 中华肾脏病杂志，2019，30(9): 712-715. [6]　李梦迪，石光，王进，等. 5例原发性甲状旁腺功能亢进症误诊为多发性骨髓瘤报道[J]. 中国实验诊断学，2019，23(10): 1787-1789. [7]　Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018[J]. American Journal of Kidney Diseases, 2018, 71(3): 423-435. [8]　刘谷全. 中药阿胶的临床用及药理作用[J]. 临床合理用药杂志，2014，7(12): 74. [9] 新珺. 浅析中医补肾健脾生血法治疗贫血的疗效[J]. 光明中医，2017，32(12): 1695. [10] Liu M, Tan H, Zhang X, et al. Hematopoietic effects and mecha-nisms of Fufang ejiao jiang on radiotherapy nd chemotherapy-in-duced myelosuppressed mice[J]. Journal of Ethnopharmacology, 2014, 152(3): 575. [11] 王璐，李祥雯，侯燕. 蔗糖铁注射液与复方阿胶浆用于产后贫血治疗的大样本随机对照研究[J]. 河北医药，2017，39(2): 242. [12] 赵静，夏晓培. 当归的化学成分及药理作用研究现状[J].临床合理用药杂志2020，13(6): 172-174. [13] 牛莉，于泓苓. 中药当归的化学成分分析与药理作用研究[J]. 中西医结合心血管病电子杂志，2018，6(21): 90，92. [14] 张梦思，邹婷，叶渊文，等. 当归多糖对衰老模型大鼠脾脏结构与功能的影响[J]. 解剖学报，2015，46(2): 257-264. [15] 李乃谦. 熟地黄活性成分药理作用的研究进展[J]. 中国处方药，2017，15(1): 14-15. [16] Huang Y, Wu C, Liu Z, et al. Optimization on preparation conditions of Rehmannia glutinosa polysaccharide liposeome and its immunological activity[J]. Carbohydrate Polymers, 2014, 104: 118-126. [17] 贾梅，郑传柱，张丽，等. 胶艾汤与四物汤对血虚模型大鼠补血功效的比较研究[J]. 中草药，2015，46(11): 1640-1644. [18] 朱嘉欢，黄小平，邓常清. 黄芪和当归的主要活性成分配伍促进衰老造血干细胞增殖作用的研究[J]. 中草药，2019，50(1): 111-119. [19] 梁同衍，刘侠，胥正娟. 四物汤对维持性血液透析患者微炎症状态的影响[J]. 中国医药指南2013，11(15): 14-15. [20] 郭传琦，戴晓霞. 加味四物汤联合促红细胞生成素治疗肾性贫血的疗效观察[J]. 中国中西医结合肾病杂志，2017，18(5): 435-436. [21] 范启兰，许春鹃，甘祝军. 四物汤对小鼠血清促红细胞生成素及其基因表达影响的实验研究[J]. 时珍国医国药，2018，19(7): 1601. [22] 段兆洁，卞海明. 八珍汤联合补铁丸治疗老年缺铁性贫血64例临床分析[J]. 航空航天医学杂志，2013，24(4): 485-486. [23] 刘世宾. 加味八珍汤联合重组人促红素注射液对肾性贫血的临床研究[D]. 济南: 山东中医药大学，2017. [24] 黄雄亮. 归脾汤治疗肾性贫血临床研究[J]. 新中医，2019，1(1): 66-70. [25] 常冬梅，张国胜. 加味归脾汤治疗慢性肾脏病患者肾性贫血的疗效及对血常规和血生化指标的影响[J]. 北方药学，2019，16(4): 104-105. [26] 谢东杰，王爱迪，刘宝山. 当归补血汤在血液疾病中作用机制的研究进展[J]. 中华中医药杂志，2018，33(6): 2488-2490. [27] 段学峰，朱冬红，王双珠，等. 当归补血汤加减联合常规疗法治疗尿毒症贫血临床观察[J]. 新中医，2018，50(5): 98-100. [28] 张吉. 针灸学[M]. 北京: 人民卫生出版社，2009. [29] 庞玉智. 当归补血汤加味结合EPO治疗慢性肾衰性贫血的临床研究[J]. 内蒙古中医药，2018，37(9): 30-31，53. [30] 毕爽丽. 温针灸联合铁剂治疗育龄妇女铁缺乏症和缺铁性贫血的临床观察[J]. 湖南中医杂志，2019，35(5): 80-82. [31] 瞿春霞. 艾灸干预贫血患者乏力的临床观察[J]. 湖南中医药大学学报，2018(38): 365. [32] 高晓婧，马秀宁，宿德民. 肾病治疗仪联合穴位贴敷辅助治疗肾性贫血的疗效观察[J]. 中国医疗器械信息，2019，25(20): 69-70, 138. [33] 黄柳莺. 补肾通络汤肾区离子导入治疗对血液透析患者贫血指标的影响[J]. 江西中医药，2012，43(7): 18-19. [34] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2018修订版)[J]. 中华肾脏病杂志，2018，34(11): 860-866. [35] Li Y, Shi H, Wang W M, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study [J]. Medicine, 2016, 95(24): e3872. [36] Chan M C, Holt-Martyn J P, Schofield C J, et al. Pharmacological targeting of the HIF hydroxylases-A new field in medicine development[J]. Molecular Aspects of Medicine, 2016, 47(48): 54-75. [37] Bonomini M, Del Vecchio L, Sirolli V, et al. New treatment approaches for the anemia of CKD[J]. American Journal of Kidney Diseases, 2016, 67(1): 133-142. [38] 于萍，张婕. 重组人促红素在外科围手术期红细胞动员的临床应用[J].食品与药品，2011，13(7): 279-282. [39] Makwana S, Basu B, Makasana Y, etal. Prefilled syringes:Aninnovation in parenteral packaging[J]. International Journal of Pharmaceutical Inverstigation, 2011, 1(4):200-206. [40] Del V L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease[J]. Expert Opinion on Drug Safety, 2016, 15(8):1021-1030. [41] Macginley R, Walker R, Irving M. KHA-CARI Guideline: use of iron in chronic kidney disease patients[J]. Nephrology(Carlton), 2013, 18(12):747-749. [42] Hsu C Y, McCulloch C E, Curhan G C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey[J]. American Society of Nephrology, 2018, 13(2): 504-510. [43] 中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组. 肾性贫血诊断与治疗中国专家共识(2014修订版)[J]. 中华肾脏病杂志，2014，30(9): 712-716. [44] KDIGO Clinical Practice Guideline Working Group. KDIGO clinical practice guideline for anemia in chronic kidney disease[J]. Kidney International Supplements, 2012, 2: 279-335. [45] Macdougall I C, Bircher A J, Eckardt K U, et al. Iron management in chronic kidney disease: conclusions from kidney disease: improving global outcomes controversies conference[J]. Kidney International, 2016, 89(1): 28-39. [46] Vaziri ND. Safety Issues in Iron Treatment in CKD[J]. Seminars in Nephrology, 2016, 36(2): 112-118. [47] Bonomini M, Del Vecchio L, Sirolli V, et al. New treatment approaches for the anemia of CKD[J]. American Journal of Kidney Diseases, 2016, 67(1): 133-142. [48] Ashby D R, Gale D P, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease[J]. Kidney International, 2009, 75(9): 976-981. [49] Zumbrennen-Bullough K, Babitt J L. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients[J]. Nephrology Dialysis Transplantation, 2014, 29(2):263-273. [50] Gerl K, Miquerol L, Todorov V T, et al. Inducible glomerular erythropoietin production in the adult kidney[J]. Kidney International, 2015, 88(6):1345-1355. [51] Gupta N, Wish Jay. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD[J]. American Journal of Kidney Diseases, 2018, 69(6): 815-826. [52] Koury M J, Haase V H. Anaemia in kidney disease: harnessing hypoxia responses for therapy[J]. Nature Reviews Nephrology, 2015, 11(7): 394-410. [53] Holdstock L, Meadowcroft A M, Maier R, et al. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia[J]. American Society of Nephrology, 2016, 27:1234-1244. [54] 方玲，常晓燕，汪燕燕，等. 罗沙司他治疗肾脏透析患者贫血有效性和安全性的Meta分析[J]. 中国医院药学杂志，2020，40(23): 2435-2439，2463. [55] Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) vrsus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6 to 19Week, open-label,active-comparator, dose-ranging, safety and exploratory efficacy study[J]. American Journal of Kidney Disease, 2016, 67: 912-924. [56] Provenzano R, Besarab A, Sun C H, et al. Oral hypoxiaInducible factor prolyl hydroxylase inhibitor roxadustat for the treatment of anemia in patients with CKD[J]. Clinical Journal of the American Society of Nephrology, 2016, 11: 982-991. [57] Flamme I, Oehme F, Ellinghaus P, et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 stimulates erythropoietin production without hypertensive effects[J]. PLoS One, 2014, 9: e111838. [58] Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. New England Journal of Medicine, 2019, 381(11): 1001-1010. [59] Chen N, Hao C, Liu B C, et al. Roxadustat treatment for anemian patients undergoing long-term dialysis[J]. New England Journal of Medicine, 2019, 381(11): 1011-1022.

相似文献/References:

[1]李开富,蒋燕丽,庞 娣,等.轻微型肝性脑病中西医治疗探讨[J].大众科技,2019,21(09):54.
　Research Progress on the Treatment of Minimal Hepatic Encephalopathy withTraditional Chinese and Western Medicine[J].Popular Science & Technology,2019,21(11):54.
[2]尚珂宇,余文君.膝骨关节炎治疗的研究进展[J].大众科技,2019,21(12):87.
　Advances in the Treatment of Knee Osteoarthritis[J].Popular Science & Technology,2019,21(11):87.
[3]张文龙 钟林芝 杨文涛.勃起功能障碍的中西医治疗研究进展[J].大众科技,2018,20(12):62.
　Research Progress of Chinese and Western Medicine Treatment of Erectile Dysfunction[J].Popular Science & Technology,2018,20(11):62.
[4]邓尧湘 黄雪霞.肾性贫血的中医药治疗近况[J].大众科技,2019,21(03):37.
　Recent Situation of Chinese Medicine Treatment of Renal Anemia[J].Popular Science & Technology,2019,21(11):37.
[5]左曜玮,彭 旋,吴艳丽,等.脑卒中后偏瘫的中西医康复治疗研究概况[J].大众科技,2019,21(06):72.
　Research Overview of Rehabilitation Treatment of Hemiplegia after Stroke withChinese and Western Medicine[J].Popular Science & Technology,2019,21(11):72.
[6]靳亚萌.中西医治疗慢性失眠的研究进展[J].大众科技,2021,23(2):61.
　Research Progress of Traditional Chinese and Western Medicine in Treating Chronic Insomnia[J].Popular Science & Technology,2021,23(11):61.
[7]鹿乔兰 梁 妮　李柱连 覃 军.中西医治疗枕神经痛的研究进展[J].大众科技,2021,23(6):53.
　Research Progress of Occipital Neuralgia treateb by Traditional Chinese and Western Medicine[J].Popular Science & Technology,2021,23(11):53.
[8]夏子茗 王润生 徐 敏 黄承军 苏正义.中西医治疗骨转移瘤的研究进展[J].大众科技,2022,24(05):92.
　Research Progress of Traditional Chinese and Western Medicine in the Treatment of Bone Metastases[J].Popular Science & Technology,2022,24(11):92.
[9]尤遵强 黄肖华 王宁泽 吴思萍 叶松生 王明锦.中西医结合治疗膝关节置换术围手术期镇痛的研究进展[J].大众科技,2023,25(8):105.
　Research Progress on Perioperative Analgesia of Total Knee Arthroplasty Treated with Integrated Traditional Chinese and Western Medicine[J].Popular Science & Technology,2023,25(11):105.

备注/Memo

备注/Memo:
【收稿日期】2021-09-12 【作者简介】耿芳（1988－），女，河北沧州人，河北省沧州中西医结合医院主治医师，硕士，研究方向为中医内科学肾病方向。 【通信作者】姜晨（1982－），女，山东菏泽人，天津中医药大学第一附属医院副主任医师，博士，硕士生导师，研究方向为中医内科学肾病方向。
更新日期/Last Update: 2022-02-14